0812 ET - Jazz Pharmaceuticals' $935 million deal to buy Chimerix carries a potential quick payoff in the form of an FDA priority review voucher. Chimerix's dordaviprone, which is under FDA review with an August 18 target action date, may be eligible for one of the vouchers, which the agency awards upon approval of drugs previously granted rare-pediatric-disease designation. The vouchers can be used to obtain priority review for another drug or sold to other companies, and a trio of recent deals has seen vouchers change hands at $150 million apiece. Chimerix rockets 70% premarket. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 08:12 ET (13:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.